CN104983679A - Sustained-release suspension with lurasidone and preparation method of sustained-release suspension - Google Patents
Sustained-release suspension with lurasidone and preparation method of sustained-release suspension Download PDFInfo
- Publication number
- CN104983679A CN104983679A CN201510350925.3A CN201510350925A CN104983679A CN 104983679 A CN104983679 A CN 104983679A CN 201510350925 A CN201510350925 A CN 201510350925A CN 104983679 A CN104983679 A CN 104983679A
- Authority
- CN
- China
- Prior art keywords
- lurasidone
- release
- lurasidone hcl
- slow
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of pharmaceutic preparations, and particularly relates to a sustained-release suspension composition with lurasidone or salt of the lurasidone and a preparation method of the sustained-release suspension composition. A sustained-release suspension comprises the lurasidone or the salt, capable of being medically accepted, of the lurasidone and a sustained-release micro-capsule coating material medicine composition. According to the preparation, the release time of lurasidone hydrochloride is effectively prolonged, and the blood concentration peak valley phenomenon caused by quick release preparations is avoided. The sustained-release suspension with the lurasidone is low in production cost and has the good taste and medicine release character, the preparation process of the sustained-release suspension with the lurasidone is convenient, and the aim of providing the preparation with the lurasidone or the salt, capable of being medically accepted, of the lurasidone for a patient is achieved, wherein the preparation is convenient to take, high in bioavailability and mild in medicine release.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of slow-release suspension composition and method of making the same comprising Lurasidone or its salt.
Background technology
Lurasidone is a kind of atypical antipsychotic, its chemistry N-[4-[4-(1,2-benzisothiazole-3-base)-1-piperazinyl]-(2R, 3R)-2 by name, 3-tetramethylene-butyl]-(1 ' R, 2 ' S, 3 ' R, 4 ' S)-2,3-dicyclo [2,2,1] heptane imidodicarbonic diamide, its chemical structural formula is as follows:
Lurasidone pharmaceutically acceptable salt is hydrochlorate.The Lurasidone HCl tablet listing of in October, 2010 U.S. FDA approval SUMITOMO CHEMICAL drugmaker, commodity are called Latuda, once a day, for schizophrenic's first-line treatment.Lurasidone is a kind of dopamine D 2/5-HT2A receptor dual antagonist, all has significant curative effect to the insane positive and negative symptoms, and Lurasidone can also improve cognitive function in addition.The less body weight that causes of Lurasidone increases, and does not cause glucose, lipid (lipoid), ECG and QT interval to change.Lurasidone tablet should be taken with food simultaneously, and recommendation initial dose is 40mg/d, and effective dosage ranges is 40-120mg/d, and maximum recommended dosage is 80mg/d.
Lurasidone HCl stable in properties, placement six months under long-time stability (temperature 30 DEG C, humidity 65%) condition, directly grinding and tabletting, crystal formation does not all change (CN201310066819.3).But Lurasidone HCl is insoluble drug, easily produce the problems such as bioavailability is low, and stripping release is incomplete.Mainly contain following several solution at present, one makes containing pregelatinized Starch, the preparation of water soluble excipient and water-soluble copolymer adhesive, and be restricted to 0.1-8 μm (US8729085B2) the mean diameter of Lurasidone HCl; The second is pulverized together with hydrophilicity condiment by Lurasidone HCl, and wherein the mean diameter of Lurasidone is restricted to 1-10 μm (CN201310749154.6); The third is that Lurasidone HCl and cyclodextrin are prepared clathrate, without the need to controlling particle diameter (CN201310252726.X); 4th kind of method prepares Lurasidone HCl glucide amorphous substance altogether, improves drug solubility (CN201410322607.1).Because cyclodextrin clathrate and amorphous substance are prepared loaded down with trivial details, and yield is lower, adopts method crude drug and xylitol pulverized altogether in this research, and control diameter of aspirin particle is 0.1-8 μm, prepares sample.
Present Lurasidone HCl commercial preparation only has ordinary tablet, but there is following shortcoming in antipsychotic drug conventional tablet: 1, cause esophageal dysmotility and suction, thus cause induction type pneumonia, be gerontal patient's common cause that especially old dementia patients is lethal; 2, there is the problem of compliance difference in mental patient when taking ordinary tablet, tablet can be hidden in Sublingual by some patients, tells after medical personnel leave, and causes the phenomenon of " vacation is taken medicine ", greatly have impact on the effect of Drug therapy.Although the more oral cavity disintegration tablet of Recent study partly can solve the problem of drug compliance difference, this medicine bitter in the mouth, taste masking difficulty, oral cavity disintegration tablet still can not meet patient demand well.
Summary of the invention
The object of the invention is to solve problems of the prior art, provide a kind of oral sustained release suspensoid containing Lurasidone HCl, effectively extend Lurasidone HCl release time, avoid the blood drug level peak valley phenomenon that quick releasing formulation causes, improve the bad mouthfeel of medicine simultaneously, solve the problems such as tablet dysphagia.
For solving the problems of the technologies described above, technical scheme provided by the invention is as follows:
A kind of Lurasidone HCl slow-release suspension, be prepared from by containing additives such as Lurasidone HCl and pharmaceutically conventional suspending agent, wetting agent, correctives, antiseptic, plasticizer, slow controlled release high molecular microencapsulated materials, effectively extend Lurasidone HCl release time, avoid the blood drug level peak valley phenomenon that quick releasing formulation causes.
Lurasidone HCl is wrapped in slow release high molecular microcapsule material in the present invention, can drug release be delayed, reach the object of long-acting mild release, the bad smell of medicine can be covered again, improve the compliance of patient.
Described slow controlled release high molecular microencapsulated material is one or more the mixture in polyacrylic resin, ethyl cellulose, cellulose acetate, polylactic acid, polyester material.Slow controlled release high molecular material need be dissolved in organic solvent, then adds in poor solvent, forms microcapsule, by medicine parcel wherein.In order to improve the pliability of microcapsule, also need in microencapsulated material to add plasticizer, comprise following material one or more: sorbitol, Polyethylene Glycol, propylene glycol, glycerol, triethyl citrate, dibutyl phthalate, diethyl phthalate, dibutyl sebacate, ethyl sebacate.
Lurasidone HCl slow-release suspension is by Lurasidone HCl 1.0-6.0%(w/v), microcapsule coating material 0.1-10%(w/v), plasticizer 0.1-10%(w/v), suspending agent 0.1-20%(w/v), antiseptic 0.001-0.02%(w/v), correctives 1-10%(w/v), wetting agent 0.01-0.2%(w/v) and ultra-pure water make.
Described wetting agent is one or more mixture of tween, span, poloxamer; Described suspending agent is the mixture of any one or more in hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, methylcellulose, sodium carboxymethyl cellulose, glycerol, propylene glycol, sorbitol, maltose alcohol, xanthan gum, carrageenan, tragakanta, polyvinylpyrrolidone, microcrystalline Cellulose, silicon dioxide, carbomer; Described antiseptic is one or more the mixture in benzalkonium bromide, benzalkonium chloride, thimerosal, nipalgin, chlorobutanol, sorbic acid; Described microcapsule coating material solvent is one or both mixture of dehydrated alcohol, methanol, acetone.
Lurasidone HCl is insoluble drug, and in order to very high bioavailability, crude drug and xylitol are pulverized by the present invention altogether, and the mass ratio of the two is 1:0.5-5, and control diameter of aspirin particle is 0.1-8 μm.
The invention provides the preparation method of Lurasidone HCl slow-release suspension, the method comprises the following steps:
(1) preparation of Lurasidone HCl suspension: add in pure water by recipe quantity wetting agent, stir, then adds Lurasidone HCl and xylitol powder thing altogether, dispersion;
(2) preparation of Lurasidone HCl microcapsule: be dissolved in solvent under microcapsule coating material and plasticizer are stirred, obtain organic facies; Organic facies added while stirring in drug suspension, stir in 30 DEG C of water-baths with 200rpm rotating speed, solidification 3h, filters, washes away the crude drug of non-enclose with pure water, dries and obtains Lurasidone HCl microcapsule;
(3) preparation of Lurasidone HCl slow-release suspension: containing suspending agent, correctives, in the solution of antiseptic, adds above-mentioned Lurasidone HCl microcapsule, is uniformly dispersed, by every bottle of 2ml subpackage, obtain Lurasidone HCl slow-release suspension.
Detailed description of the invention
Embodiment 1-3
Prescription forms:
| Supplementary material title | Effect | Embodiment 1 (g) | Embodiment 2 (g) | Embodiment 3 (g) |
| Lurasidone HCl | Principal agent | 2 | 4 | 6 |
| Xylitol | Water soluble adjuvant | 2 | 4 | 6 |
| Tween | Wetting agent | 0.05 | 0.1 | 0.15 |
| Polyacrylic resin RS | Microcapsule coating material | 2.5 | 5 | 7.5 |
| Triethyl citrate | Plasticizer | 0.5 | 1 | 1.5 |
| Xanthan gum | Suspending agent | 2 | 4 | 6 |
| Sucrose | Correctives | 2 | 4 | 6 |
| Ethyl hydroxybenzoate | Antiseptic | 0.005 | 0.01 | 0.015 |
| Pure water | Disperse medium | To 100ml | To 100ml | To 100ml |
Preparation technology:
(1) preparation of Lurasidone HCl suspension: added in 200ml pure water by 0.5g tween, stir, then adds Lurasidone HCl and xylitol (1:1) powder thing 40g altogether, dispersion;
(2) preparation of Lurasidone HCl microcapsule: be dissolved in 500ml ethanol under 25g polyacrylic resin RS and 5g triethyl citrate are stirred, obtain organic facies; Organic facies added while stirring in drug suspension, stir in 30 DEG C of water-baths with 200rpm rotating speed, solidification 3h, filters, and with pure water 3 times, washes away the crude drug of non-enclose, dries and obtains Lurasidone HCl microcapsule, calculates Lurasidone HCl microcapsule content;
(3) preparation of Lurasidone HCl slow-release suspension: recipe quantity xanthan gum, sucrose, ethyl hydroxybenzoate are added in 100ml water, stir, add above-mentioned Lurasidone HCl microcapsule by recipe quantity, be uniformly dispersed, press 2ml subpackage for every bottle, obtain Lurasidone HCl slow-release suspension.
Embodiment 4-6
Prescription forms:
| Supplementary material title | Effect | Embodiment 4 (g) | Embodiment 5 (g) | Embodiment 6 (g) |
| Lurasidone HCl | Principal agent | 4 | 4 | 4 |
| Xylitol | Water soluble adjuvant | 2 | 4 | 6 |
| Tween | Wetting agent | 0.1 | 0.1 | 0.1 |
| Ethyl cellulose | Microcapsule coating material | 2.5 | 5 | 7.5 |
| Diethyl phthalate | Plasticizer | 0.5 | 1 | 1.5 |
| Hypromellose | Suspending agent | 4.5 | 4.5 | 4.5 |
| Sucrose | Correctives | 2 | 3 | 4 |
| Sorbic acid | Antiseptic | 0.01 | 0.01 | 0.01 |
| Pure water | Disperse medium | To 100ml | To 100ml | To 100ml |
Preparation technology:
According under summary of the invention item, the preparation method of Lurasidone HCl slow-release suspension carries out formula preparation, selects ethanol as the solvent of microcapsule coating material.Should be noted the calculating of microcapsules medicine thing content, and drop into corresponding microcapsule according to result of calculation.
Dissolution test
The sample of Example 1-6, according to dissolution method (Chinese Pharmacopoeia version in 2010 two annex Ⅹ C second methods), with 900ml pH3.8 buffer for dissolution medium, rotating speed is 50rpm, operate in accordance with the law, get dissolution fluid 10ml after certain hour, filter, get subsequent filtrate (embodiment 2-6 sample needs corresponding dilution) as need testing solution; Separately get Lurasidone HCl reference substance, add a small amount of methanol and make dissolving, then be diluted to 44 μ g/ml reference substance solution with dissolution medium.Get above-mentioned two kinds of solution, according to ultraviolet visible spectrophotometry (Chinese Pharmacopoeia version in 2010 two annex IV A), measure absorbance at the wavelength place of 315nm, calculate stripping quantity.Embodiment sample and control formulation (former grind as tablet) stripping result is as follows:
| Time (h) | Control formulation | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| 0.25 | 85.25 | 10.33 | 9.23 | 12.35 | 9.14 | 12.74 | 10.76 |
| 0.5 | 90.90 | 18.45 | 19.15 | 20.78 | 21.39 | 22.14 | 20.38 |
| 1 | 98.54 | 30.56 | 28.45 | 32.45 | 32.78 | 32.66 | 31.38 |
| 2 | - | 50.34 | 49.78 | 52.82 | 51.71 | 50.78 | 51.09 |
| 4 | - | 70.78 | 68.01 | 69.74 | 70.39 | 70.28 | 69.84 |
| 6 | - | 82.56 | 79.23 | 80.13 | 82.53 | 84.47 | 81.78 |
| 8 | - | 90.98 | 87.01 | 89.78 | 92.14 | 92.90 | 90.56 |
| 12 | - | 95.02 | 96.56 | 98.99 | 99.02 | 97.72 | 97.46 |
From experimental result, rapidly, 1h discharges the release of control formulation Chinese medicine completely.Homemade slow-release suspension release is mild, can reach 12h slow releasing, and between each embodiment, rate of release is substantially suitable.In embodiment 1-3, microcapsule has same composition, and only suspending agent, correctives, antiseptic consumption are slightly different, illustrate that the main process of Drug controlled release is microcapsule coating.In embodiment 4-6, microcapsule prescription is slightly different, but microcapsule coating material usage major effect microcapsule yield, can not drug release be affected within the specific limits.
Mouthfeel, sedimentation volume ratio and dispersion experiment again
Mouthfeel: by 6 healthy volunteer's buccal administration, evaluate its bitterness, bitterness is divided into: " +++ " bitterness is strong; " ++ " bitterness is obvious, can stand; "+" slight bitterness; "-" is without bitterness.
Sedimentation volume ratio: operate by 2010 editions pharmacopeia, two annex I O, apparatus plug graduated cylinder measures test sample 50ml, close plug, firmly jolting 1min, writes down the beginning height H of suspended matter
0, leave standstill 3h, write down the final height H of suspended matter, be calculated as follows: sedimentation volume ratio=H/H
0, by regulation, the sedimentation volume ratio of oral suspensions should be not less than 0.90.
Again dispersion experiment: slow-release suspension is placed in 100ml graduated cylinder, rotates with the speed of 20rpm, and through 20min, observe bottom graduated cylinder whether have precipitum, can precipitum disperse after jolting again, evaluates dispersibility again.
By mouthfeel, sedimentation volume ratio and again dispersion experiment embodiment suspensoid is evaluated, the results are shown in following table.
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Mouthfeel | - | - | - | - | - | - |
| Sedimentation volume ratio | 0.93 | 0.96 | 0.97 | 0.96 | 0.97 | 0.97 |
| Again dispersion experiment | Precipitum is easy to dispersion | Without precipitum | Without precipitum | Without precipitum | Without precipitum | Without precipitum |
From sensory test result, medicine is after microcapsule coating, and bitterness is covered up well, without bitterness.Sedimentation volume ratio and dispersion experiment display again in addition, each embodiment sample all meets the requirements.
Claims (6)
1. a Lurasidone HCl slow-release suspension, it is characterized in that: be prepared from by containing additives such as Lurasidone HCl and pharmaceutically conventional suspending agent, wetting agent, correctives, antiseptic, plasticizer, slow controlled release high molecular microencapsulated materials, effectively extend Lurasidone HCl release time, avoid the blood drug level peak valley phenomenon that quick releasing formulation causes.
2. Lurasidone HCl slow-release suspension according to claim 1, described slow controlled release high molecular microencapsulated material is one or more the mixture in polyacrylic resin, ethyl cellulose, cellulose acetate, polylactic acid, polyester material; And also add plasticizer in described microencapsulated material, comprise following material one or more: sorbitol, Polyethylene Glycol, propylene glycol, glycerol, triethyl citrate, dibutyl phthalate, diethyl phthalate, dibutyl sebacate, ethyl sebacate.
3. Lurasidone HCl slow-release suspension according to claim 1, is characterized in that: by Lurasidone HCl 1.0-6.0%(w/v), microcapsule coating material 0.1-10%(w/v), plasticizer 0.1-10%(w/v), suspending agent 0.1-20%(w/v), antiseptic 0.001-0.02%(w/v), correctives 1-10%(w/v), wetting agent 0.01-0.2%(w/v) and ultra-pure water make.
4. Lurasidone HCl slow-release suspension according to claim 1, described wetting agent is one or more mixture of tween, span, poloxamer; Described suspending agent is the mixture of any one or more in hydroxypropyl emthylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, methylcellulose, sodium carboxymethyl cellulose, glycerol, propylene glycol, sorbitol, maltose alcohol, xanthan gum, carrageenan, tragakanta, polyvinylpyrrolidone, microcrystalline Cellulose, silicon dioxide, carbomer; Described antiseptic is one or more the mixture in benzalkonium bromide, benzalkonium chloride, thimerosal, nipalgin, chlorobutanol, sorbic acid; Described microcapsule coating material solvent is one or both mixture of dehydrated alcohol, methanol, acetone.
5. Lurasidone HCl slow-release suspension according to claim 1, crude drug and xylitol are pulverized altogether, and the mass ratio of the two is 1:0.5-5, and control diameter of aspirin particle is 0.1-8 μm.
6. according to claim 1, a kind of preparation method of Lurasidone HCl slow-release suspension comprises the following steps:
(1) preparation of Lurasidone HCl suspension: add in pure water by recipe quantity wetting agent, stir, then adds Lurasidone HCl and xylitol powder thing altogether, dispersion;
(2) preparation of Lurasidone HCl microcapsule: be dissolved in solvent under microcapsule coating material and plasticizer are stirred, obtain organic facies; Organic facies added while stirring in drug suspension, in 30 DEG C of water-baths, stir with 200rpm rotating speed, solidification 3h, filters, washes away the crude drug of non-enclose with pure water, dries and obtains Lurasidone HCl microcapsule;
(3) preparation of Lurasidone HCl slow-release suspension: containing suspending agent, correctives, in the solution of antiseptic, adds above-mentioned Lurasidone HCl microcapsule, is uniformly dispersed, by every bottle of 2ml subpackage, obtain Lurasidone HCl slow-release suspension.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510350925.3A CN104983679A (en) | 2015-06-24 | 2015-06-24 | Sustained-release suspension with lurasidone and preparation method of sustained-release suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510350925.3A CN104983679A (en) | 2015-06-24 | 2015-06-24 | Sustained-release suspension with lurasidone and preparation method of sustained-release suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104983679A true CN104983679A (en) | 2015-10-21 |
Family
ID=54295673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510350925.3A Pending CN104983679A (en) | 2015-06-24 | 2015-06-24 | Sustained-release suspension with lurasidone and preparation method of sustained-release suspension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983679A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107320444A (en) * | 2016-04-28 | 2017-11-07 | 成都康弘药业集团股份有限公司 | A kind of drug solution containing Lurasidone HCl and preparation method thereof |
| CN107998093A (en) * | 2017-12-17 | 2018-05-08 | 佛山市弘泰药物研发有限公司 | A kind of Lurasidone HCl sustained release tablets and preparation method thereof |
| CN109640996A (en) * | 2016-08-31 | 2019-04-16 | 大日本住友制药株式会社 | Aqueous suspension type preparation |
| WO2019167977A1 (en) * | 2018-02-28 | 2019-09-06 | 大日本住友製薬株式会社 | Aqueous suspension-type pharmaceutical preparation |
| WO2019167978A1 (en) * | 2018-02-28 | 2019-09-06 | 大日本住友製薬株式会社 | Aqueous suspension-type pharmaceutical preparation having controlled dissolution |
| CN110693843A (en) * | 2019-10-31 | 2020-01-17 | 常州市阳光药业有限公司 | Lurasidone hydrochloride hydrophilic gel skeleton tablet and preparation method thereof |
| CN111437256A (en) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | Riluzole sustained-release oral suspension |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058529A (en) * | 2010-12-30 | 2011-05-18 | 东莞广州中医药大学中医药数理工程研究院 | Ondansetron-containing oral liquid sustained-release preparation and preparation method thereof |
| CN103751139A (en) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | Lurasidone orally disintegrating tablet |
| CN104306330A (en) * | 2014-09-24 | 2015-01-28 | 万特制药(海南)有限公司 | Memantine hydrochloride slow-release suspension and preparation method thereof |
| CN104606133A (en) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | Oral lurasidone suspension and preparation method thereof |
-
2015
- 2015-06-24 CN CN201510350925.3A patent/CN104983679A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058529A (en) * | 2010-12-30 | 2011-05-18 | 东莞广州中医药大学中医药数理工程研究院 | Ondansetron-containing oral liquid sustained-release preparation and preparation method thereof |
| CN103751139A (en) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | Lurasidone orally disintegrating tablet |
| CN104306330A (en) * | 2014-09-24 | 2015-01-28 | 万特制药(海南)有限公司 | Memantine hydrochloride slow-release suspension and preparation method thereof |
| CN104606133A (en) * | 2015-01-07 | 2015-05-13 | 万特制药(海南)有限公司 | Oral lurasidone suspension and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107320444A (en) * | 2016-04-28 | 2017-11-07 | 成都康弘药业集团股份有限公司 | A kind of drug solution containing Lurasidone HCl and preparation method thereof |
| CN107320444B (en) * | 2016-04-28 | 2021-02-26 | 成都康弘药业集团股份有限公司 | Pharmaceutical solution containing lurasidone hydrochloride and preparation method thereof |
| CN109640996A (en) * | 2016-08-31 | 2019-04-16 | 大日本住友制药株式会社 | Aqueous suspension type preparation |
| CN107998093A (en) * | 2017-12-17 | 2018-05-08 | 佛山市弘泰药物研发有限公司 | A kind of Lurasidone HCl sustained release tablets and preparation method thereof |
| WO2019167977A1 (en) * | 2018-02-28 | 2019-09-06 | 大日本住友製薬株式会社 | Aqueous suspension-type pharmaceutical preparation |
| WO2019167978A1 (en) * | 2018-02-28 | 2019-09-06 | 大日本住友製薬株式会社 | Aqueous suspension-type pharmaceutical preparation having controlled dissolution |
| EP3760206A4 (en) * | 2018-02-28 | 2021-11-03 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous suspension-type pharmaceutical preparation having controlled dissolution |
| CN111437256A (en) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | Riluzole sustained-release oral suspension |
| CN110693843A (en) * | 2019-10-31 | 2020-01-17 | 常州市阳光药业有限公司 | Lurasidone hydrochloride hydrophilic gel skeleton tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104983679A (en) | Sustained-release suspension with lurasidone and preparation method of sustained-release suspension | |
| JP7251891B2 (en) | Pharmaceutical formulation with excellent photostability and dissolution | |
| ES2731601T3 (en) | Delayed-release oral dosing compositions containing amorphous CDDO-Me | |
| CN102836159B (en) | Dasatinib dispersoid, preparation method thereof and application thereof in tablets | |
| JP6618099B2 (en) | Solid formulation with excellent stability | |
| EP4079295A1 (en) | Composition having improved solubility and bioavailability of olaparib | |
| CN102178956B (en) | Preparation, medical application and composition of 20S-protopanaxadiol beta-cyclodextrin inclusion compound | |
| CN104906038A (en) | Aripiprazole nanocrystal and preparation method thereof | |
| CN100998551A (en) | Oral cavity quick dissolved film containing civeran, and method for preparing the same | |
| CN104546807A (en) | Olanzapine oral fast dissolving film preparation | |
| CN104940152B (en) | A kind of pharmaceutical composition containing butanedioic acid Solifenacin | |
| WO2006109737A1 (en) | Pranlukast hydrate-containing preparation having relieved bitterness | |
| CN108066312B (en) | Palbociclib pharmaceutical composition and preparation method thereof | |
| CN107613978B (en) | Pharmaceutical composition of MEK inhibitor and preparation method thereof | |
| CN103845332B (en) | A kind of Dasatinib Pharmaceutical composition and preparation method thereof | |
| CN102552208B (en) | Daidzein solid dispersion micro-pill capsule and preparation method thereof | |
| JP6590436B1 (en) | Solid formulation with excellent stability | |
| WO2023093640A1 (en) | Darolutamide pharmaceutical composition, preparation method therefor and use thereof | |
| CN114533735A (en) | Lurasidone hydrochloride pharmaceutical composition and preparation method thereof | |
| CN105169409A (en) | Compound of propranolol or medicinal salt thereof and ion exchange resin and suspension of compound | |
| TW202038918A (en) | Pharmaceutical composition | |
| CN111437256A (en) | Riluzole sustained-release oral suspension | |
| CN108553416A (en) | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride | |
| CN112236146B (en) | Solid dosage form with excellent stability | |
| CN107137374B (en) | Solid pharmaceutical composition of palonosetron |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151021 |